ClinicalTrials.gg
CompletedNCT01968057Updated Jun 6, 2017Results posted

A Study of Baricitinib and Ciclosporin in Healthy Participants

A Phase 1 interventional study of Baricitinib and Ciclosporin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-06-06.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effects of ciclosporin on the amount of baricitinib that is absorbed into the blood stream and the time it takes to remove baricitinib from the body. The study will also look at how well-tolerated and safe baricitinib is, when given alone and in combination with ciclosporin. Side effects will be documented. The study will last approximately 6 days from the first dose to the end of the study (not including screening or follow-up).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants: agree to use 2 reliable methods of with female partners of during the study and for at least 3 months following the last dose of study drug
  • Female participants: women not of childbearing potential due to surgical sterilization confirmed by medical history, or menopause
  • Have a of 18.0 to 29.0 kilograms per meter squared (kg/m\^2), inclusive
  • Have clinical laboratory test results within the normal reference range
  • Have normal renal function
  • Have normal blood pressure and pulse rate

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in a clinical trial involving a study drug or off-label use of a drug or device, or are concurrently enrolled in any other type of medical research
  • Have completed or discontinued within the last 90 days from a clinical trial involving a study drug
  • Are participants who have previously completed or withdrawn from this study or any other study investigating baricitinib, and have previously received baricitinib
  • Have known allergies to baricitinib, ciclosporin, related compounds, or any components of the baricitinib or ciclosporin formulations, or history of significant atopy
  • Have an abnormality in the 12-lead (ECG)
  • Have a history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Have a current or recent history of a bacterial, fungal, parasitic, viral (not including rhinopharyngitis), or mycobacterial infection
  • Have had symptomatic herpes zoster or herpes simplex infection within 90 days prior to the first dose
  • Have an (ANC) less than 2 × 10\^9 cells/liter(L) [2000 cells/microliter (μL)] at screening or day prior to first dose of study drug
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of infection and/or positive hepatitis C antibody
  • Show evidence of infection and/or positive hepatitis B surface antigen
  • Have a history of active tuberculosis within the last 5 years
  • Are women who are lactating or pregnant
  • Have been exposed to a within 12 weeks prior to the first dose or expected to need/receive a live vaccine (including herpes zoster vaccination) during the course of the study
  • Intend to use over-the-counter or prescription medication (including salicylate drugs) and/or herbal supplements within 14 days prior to dosing and during the study or intended use of vitamin supplements from Day 1 until discharge from the Clinical Research Unit (CRU)
  • Have consumed or intend to consume grapefruit, Seville oranges, or products containing these fruits within 7 days prior to the first dose and until discharge from the CRU
  • Have donated or lost blood of more than 500 milliliters (mL) within the last 3 months
  • Have an average weekly alcohol intake that exceeds 28 units per week (males) and 21 units per week (females), or are unwilling to stop alcohol consumption from 48 hours prior to the first dose until discharge from the CRU at the end of Period 2
  • History of, in the opinion of the investigator, excessive methylxanthine use within the previous 6 months, such as greater than (>) 6 cups of coffee (or equivalent) per day
  • Currently smoke more than 10 cigarettes per day
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Baricitinib

    Single oral dose of 4 milligrams (mg) baricitinib on Day 1

    Drug: Baricitinib

  • Experimental
    Baricitinib + Ciclosporin

    Single oral dose of 4 mg baricitinib co-administered with a single oral dose of 600 mg ciclosporin on Day 4

    Drug: Baricitinib · Drug: Ciclosporin

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib

    Time frame: Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose

  2. PK: Area Under the Concentration Curve From Time Zero to Infinity [AUC (0-∞)] of Baricitinib

    Time frame: Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose

  3. PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib

    Time frame: Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose

07

Results

Posted Apr 21, 2017

Participant flow

Period 1 (Day 1 to Predosing Day 4)
Participant flow — Period 1 (Day 1 to Predosing Day 4)
MilestoneBaricitinib + Ciclosporin
Started18
Received baricitinib18
Completed18
Not completed0
Period 2 (At Dosing Day 4 to Day 7)
Participant flow — Period 2 (At Dosing Day 4 to Day 7)
MilestoneBaricitinib + Ciclosporin
Started18
Received baricitinib + ciclosporin18
Completed18
Not completed0

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
Time frame:
Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose
Reported as:
Geometric mean · nanograms/milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib
nanograms/milliliter (ng/mL)BaricitinibBaricitinib + Ciclosporin
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib36.2 ± 2535.8 ± 22
PrimaryPK: Area Under the Concentration Curve From Time Zero to Infinity [AUC (0-∞)] of Baricitinib
Time frame:
Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose
Reported as:
Geometric mean · nanograms*hour/milliliter (ng*h/mL)
PK: Area Under the Concentration Curve From Time Zero to Infinity [AUC (0-∞)] of Baricitinib
nanograms*hour/milliliter (ng*h/mL)BaricitinibBaricitinib + Ciclosporin
PK: Area Under the Concentration Curve From Time Zero to Infinity [AUC (0-∞)] of Baricitinib241 ± 24311 ± 26
PrimaryPK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
Time frame:
Days 1 and 4: predose of baricitinib, 0.5, 1, 2, 4, 6, 8, 12, 16, 24, 36, 48 and 72 hours postdose
Reported as:
Median · hours
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib
hoursBaricitinibBaricitinib + Ciclosporin
PK: Time of Maximum Observed Drug Concentration (Tmax) of Baricitinib1.00 (0.50 to 1.00)2.00 (0.50 to 4.00)

Adverse events

Collected over Baseline through study completion (up to Day 14).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Baricitinib—0/18 (0%)9/18 (50%)
Baricitinib + Ciclosporin—0/18 (0%)15/18 (83.3%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventBaricitinibBaricitinib + Ciclosporin
NauseaGastrointestinal disorders0/188/18
HeadacheNervous system disorders3/188/18
Feeling hotGeneral disorders0/186/18
DysmenorrhoeaReproductive system and breast disorders1/31/3
DizzinessNervous system disorders0/185/18
ParaesthesiaNervous system disorders0/183/18
ConstipationGastrointestinal disorders2/181/18
Defaecation urgencyGastrointestinal disorders0/182/18
Catheter site related reactionGeneral disorders0/182/18
FatigueGeneral disorders0/182/18

Baseline characteristics

All enrolled participants

Age, Continuous
Age, Continuous(years)Baricitinib + Ciclosporin
Mean38.4 ± 12.7
Sex: Female, Male
Sex: Female, Male(Participants)Baricitinib + Ciclosporin
Female3
Male15
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Baricitinib + Ciclosporin
Hispanic or Latino0
Not Hispanic or Latino18
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Baricitinib + Ciclosporin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White18
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Baricitinib + Ciclosporin
United Kingdom18
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2013, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2017, 3 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2013
First posted
Oct 23, 2013
Start
Oct 2013
Primary completionActual
Dec 2013
CompletionActual
Dec 2013
Results first posted
Apr 21, 2017
Last update
Jun 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01968057
Responsible party
Sponsor
First posted
Oct 23, 2013
Start date
Oct 2013
Primary completion
Dec 2013
Completion
Dec 2013
Results posted
Apr 21, 2017
Last update
Jun 6, 2017

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Baricitinib · Cyclosporine

Start the discussion